• Autoantibody repertoires against native and denatured DNA, RNAs, extractable nuclear antigens (ENA), and soluble nuclear antigens defined lupus subtypes and activity, with cross-reactivity to polynucleotides and DNA complexes guiding diagnostic phenotypes [5], [14], [19], [13], [9], [4], [18], [1].

• Immunologic activity markers correlate with organ involvement, notably renal disease, showing that low complement and antibodies to DNA associate with nephritis and influence disease course [2], [12], [17], [15].

• Immunodiagnostic methodology advanced lupus research—from LE cell tests to fluorescent antibody techniques and antigen-specific assays—enabling detection of antinuclear antibodies and DNA-binding reactivity across patient cohorts [11], [10], [9], [1], [17], [14], [18].

• Clinical phenotypes and natural history reveal heterogeneity in SLE—from vasculitis and dermatologic signs to renal involvement and familial clustering—documented in landmark cohort studies and disease histories [3], [8], [20], [12].

• Cytotoxic immune mechanisms and lymphocyte-targeted toxins characterize lupus immunopathology, with lymphocytotoxic antibodies and T-cell–specific effects shaping disease activity and intercellular interactions [6], [7].